Results 331 to 340 of about 2,888,163 (384)

Phosphodiesterase inhibitors and the eye

Clinical & Experimental Ophthalmology, 2009
AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M. Kerr, Helen V. Danesh-Meyer
openaire   +2 more sources

Phosphodiesterase‐5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use

Annals of the American Thoracic Society, 2018
Rationale: Care of patients with pulmonary hypertension is complex. Although pulmonary vasodilators are effective for Group 1 pulmonary hypertension, clinical guidelines and the Choosing Wisely Campaign recommend against routine use for Groups 2 and 3 ...
Deborah Kim, K. M. Lee, M. Freiman, R. Powell, E. Klings, S. Rinne, Donald R. Miller, A. Rose, R. Wiener   +8 more
semanticscholar   +1 more source

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2018
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema Zebda, Amy S. Paller
openaire   +3 more sources

In Defense of Phosphodiesterase 5 Inhibitors

JAMA Ophthalmology, 2022
Not ...
Belladelli, Federico, Del Giudice, Francesco, Eisenberg, Michael L   +2 more
openaire   +3 more sources

An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.

JAMA dermatology, 2014
An Oral Phosphodiesterase Inhibitor (Apremilast) for Inflammatory Rosacea in Adults: A Pilot Study Rosacea is a chronic skin disorder characterized by facial flushing, persistent erythema, telangiectasias, and inflammatory papules and pustules.
B. Thompson, Megan Furniss, Wenjing Zhao, B. Chakraborty, Julian M. Mackay-Wiggan   +4 more
semanticscholar   +1 more source

Phosphodiesterase Inhibitors and Cerebral Vasospasm

Archives of Neurology, 1975
Experimental cerebral vasospasm was studied in cat and monkey models. In the cat, the basilar artery was exposed by a transclival approach and spasm induced by the application of blood to the vessel. In the monkey, spasm was produced by injecting blood into the subarachnoid space.
Eugene S. Flamm, Joseph P. Lin, Jhino Kim, Joseph Ransohoff   +3 more
openaire   +4 more sources

Phosphodiesterase-5 Inhibitors

2013
Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A. Cockrill, Aaron B. Waxman
openaire   +3 more sources

Xanthines and Phosphodiesterase Inhibitors

2016
Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
Clive P. Page, Domenico Spina
openaire   +2 more sources

Inhibitors of phosphodiesterases in the treatment of cough

Respiratory Physiology & Neurobiology, 2018
A group of 11 enzyme families of metalophosphohydrolases called phosphodiesterases (PDEs) is responsible for a hydrolysis of intracellular cAMP and cGMP. Xanthine derivatives (methylxanthines) inhibit PDEs without selective action on their single isoforms and lead to many pharmacological effects, e.g.
Daniela Mokra, Anna Urbanova, Martin Kertys, Juraj Mokry   +3 more
openaire   +3 more sources

Phosphodiesterase inhibitors in psychiatric disorders

Psychopharmacology, 2023
Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi, Ehsan, Nassireslami, Mojtaba, Yousefi Zoshk, Yasaman, Hosseini, Kourosh, Abbasian, Mohsen, Chamanara   +5 more
openaire   +2 more sources